TeamDrive
RUS

Corneal inlays need a boost from eye care providers

12 January 2018

Healio

CURRENTLY VIEWING

John A. Hovanesian, MD, FACS, focuses his blog on real-world comanagement cases with valuable take-home messages. Dr. Hovanesian is a specialist in cornea, external ocular disease and refractive and cataract surgery with Harvard Eye Associates in Laguna Hills, Calif., a clinical instructor at UCLA Jules Stein Eye Institute and a member of the Primary Care Optometry 

The Raindrop corneal inlay from ReVision Optics and the AcuFocus Kamra corneal inlay have been implanted in thousands of eyes.

Ninety-five percent of patients with these devices report being quite satisfied, according to surveys, and virtually all implanting surgeons report they would recommend the procedures to their colleagues.

Personally, I have implanted corneal inlays in two close friends. One received the Raindrop about 3 years ago as part of the FDA study, and the other received the Kamra more recently. I regularly hear from both of them about how much they enjoy their freedom from glasses and their ability to be the only one at the restaurant table to read the menu without glasses.

This is an exciting time in keratorefractive surgery. We have a booming generation of millennials who are interested in this type of procedure and an even larger swelling population of presbyopic baby boomers who need near vision correction. Both the SMILE procedure (Zeiss) and these new inlays offer platforms for future development that will take us beyond the capabilities of LASIK and PRK.

But it is not enough that companies develop these technologies. Surgeons have to learn to adopt them, and optometrists must recommend them, for our science to move forward. This takes effort and investment. Adding procedures to the ophthalmologist’s skill set takes us away from our routine and tests our surgical skill, but these are very learnable procedures, building upon skills learned in LASIK. The added equipment is minimal, and the excitement generated by offering a new procedure is very good for our practices.

Most of all, these procedures are extremely gratifying. My faith in the technology that drove me to offer them to personal friends has been rewarded, and I certainly hope every eye care provider will give these new technologies a chance to improve the lives of their own patients.

Disclosure: Hovanesian reports he is a consultant for Zeiss, ReVision Optics and AcuFocus.

Source


Previous publication Next publication

Media Center

  • 22 June 2018

    Drug shortages again on the rise after 5 years of improvements, FDA says

    After 5 years of declines in the number of new drug shortages in the U.S., they jumped to 39 last year from 26 in the two preceding years. And while that is a far cry from the peak of more than 250 registered in 2011, the FDA acknowledges that many of the current shortages have been for critical drug products and “are having a tangible impact on patients.”

  • 22 June 2018

    Pfizer’s 'Living With Cancer' wowed Cannes attendees, if not the pharma jury

    A Pfizer documentary film about five patients living with cancer may have inspired more fanfare at Cannes Lions Health than it did in the eight months since its launch. The “This is Living With Cancer” film and its associated campaign was shortlisted for a pharma award at the annual ad festival and was heaped with praise after Pfizer presented it in an open session.

  • 21 June 2018

    EvaluatePharma World Preview 2018, Outlook to 2024

    EvaluatePharma World Preview 2018, Outlook to 2024

    And according to EvaluatePharma’s World Preview 2018, we are looking at an industry set to experience sales accelerating from the sluggish levels following the financial crisis, to annual compound growth of over 6% between now and 2024. 

  • 21 June 2018

    Russian equipment for storage of thermolabile drugs was delivered to China

    POZIS JSC, an affiliate of Techmash concern of Rostec Corporation, for the first time delivered Russian medical equipment to Hong Kong. Under the contract, the customer received HF-140 POZIS, pharmaceutical refrigerators designed for storage of thermolabile drugs, and RBC-2, new generation compact bactericidal recirculators for air disinfection.

Read more